The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

Studies designed, executed and funded by Alkermes, Inc.

Filter Publications
Therapeutic Area:
Publication Type:
Showing 10 of 99 results
Sort by date: Ascending
Nov 2012
Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection
Journal of Studies on Alcohol and Drugs
AUTHOR(S)

Mitchell MC, Memisoglu A, Silverman BL

View on PubMed
Clinical
Opioid Use Disorder
Mar 2013
Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study
NeuroImage
AUTHOR(S)

Lukas SE, Lowen SB, Lindsey KP, Conn N, Tartarini W, Rodolico J, Mallya G, Palmer C, Penetar DM

View on PubMed
Clinical
Alcohol Use Disorder
Sep 2013
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness
Addiction
AUTHOR(S)

Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL

View on PubMed
Clinical
Opioid Use Disorder
Nov 2013
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
Patient Preference and Adherence
AUTHOR(S)

Kaplan, G, Casoy, J, Zummo, J

View on PubMed
Review/Commentary
Schizophrenia
Apr 2015
Treating opioid dependence with injectable extended-release naltrexone (XR-NTX) who will respond?
Journal of Addiction Medicine
AUTHOR(S)

Nunes EV, Krupitsky E, Ling W, Zummo J, Memisoglu A, Silverman BL, Gastfriend DR

View on PubMed
Clinical
Opioid Use Disorder
Aug 2015
A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia
The Journal of Clinical Psychiatry
AUTHOR(S)

Meltzer HY, Risinger R, Nasrallah HA, Du Y, Zummo J, Corey L, Bose A, Stankovic S, Silverman BL, Ehrich EW.

View on PubMed
Clinical
Schizophrenia
Mar 2016
Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia
International Clinical Psychopharmacology
AUTHOR(S)

Citrome L, Du Y, Risinger R, Stankovic S, Claxton A, Zummo J, Bose A, Silverman BL, Ehrich EW

View on PubMed
Clinical
Schizophrenia
Nov 2016
Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia
The Journal of Clinical Psychiatry
AUTHOR(S)
Nasrallah HA, Newcomer JW, Risinger R, Du Y, Zummo J, Bose A, Stankovic S, Silverman BL, Ehrich EW
View on PubMed
Clinical
Schizophrenia
Jan 2017
Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia
Schizophrenia Research
AUTHOR(S)

Targum SD, Risinger R, Du Y, Pendergrass JC, Jamal HH, Silverman BL

View on PubMed
Clinical
Schizophrenia
Apr 2017
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine
American Journal of Psychiatry
AUTHOR(S)
Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM, Levin FR, Dakwar E, Mariani JJ, Nunes EV
View on PubMed
Clinical
Opioid Use Disorder